نتایج جستجو برای: aryoseven

تعداد نتایج: 18  

Journal: :Iranian journal of pathology 2016
Gholamreza Toogeh Hassan Abolghasemi Peyman Eshghi Mohammadreza Managhchi Mohammadreza Shaverdi-Niasari Katayoon Karimi Samin Roostaei Neda Emran Alireza Abdollahi

BACKGROUND Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. METHODS This single-center, descriptive, cross sectional study was carried out in Thrombus an...

2016
Mina Golestani Peyman Eshghi Hamid Reza Rasekh Abdoll Majid Cheraghali Jamshid Salamzadeh Majid Naderi Mohammad Reza Managhchi Hamid Hoorfar Gholam Reza Toogeh Ali Imani Mohammad Taghi Khodayari Behnaz Habibpanah Razieh Hantooshzadeh

Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost-effectiv...

Alireza Abdollahi, Gholamreza Toogeh, Hassan Abolghasemi Katayoon Karimi Mohammadreza Managhchi Mohammadreza Shaverdi-niasari Neda Emran Peyman Eshghi, Samin Roostaei

Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...

Journal: :iranian journal of pathology 0
gholamreza toogeh thromboses hemostasis research center, tehran university of medical sciences, tehran, iran hassan abolghasemi pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran peyman eshghi pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran mohammadreza managhchi thromboses hemostasis research center, tehran university of medical sciences, tehran, iran mohammadreza shaverdi-niasari thromboses hemostasis research center, tehran university of medical sciences, tehran, iran katayoon karimi thromboses hemostasis research center, tehran university of medical sciences, tehran, iran samin roostaei

background: recombinant activated factor vii induces hemostasis in patients with coagulopathy disorders. aryoseven™ as a safe iranian recombinant activated factor vii has been available on our market. this study was performed to establish the safety of aryoseven on patients with coagulopathy disorder. methods: this single-center, descriptive, cross sectional study was carried out in thrombus an...

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

2017
Maryam Tabarzad Marzieh Jafari Nastaran Nafissi-varcheh

BACKGROUND Among diverse protein purification systems, affinity chromatography is the most attractive one in the purification process of coagulation factors. Coagulation factor VII is a plasma serine protease that has a significant role in natural human hemostasis and its recombinant form such as AryoSeven™, has been applied in clinical treatment of bleeding disorders. Immunoaffinity chromatogr...

Journal: :iranian journal of pharmaceutical research 0
mina golestani school of pharmacy, shahid beheshti university of medical sciences, tehran, iran, iranian center of excellence in health management, faculty of management and medical informatics, tabriz university of medical sciences, tabriz, iran peyman eshghi pediatric hematology and oncology , pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran hamid reza rasekh school of pharmacy, shahid beheshti university of medical sciences, tehran, iran abdoll majid cheraghali school of pharmacy, university of baqiyatallah medical sciences, tehran, iran jamshid salamzadeh school of pharmacy, shahid beheshti university of medical sciences, tehran,iran majid naderi genetics of non-communicable disease research center, zahedan university of medical sciences, zahedan, iran

abstract nowadays, bypassing agents such as recombinant activated factor vii (rfviia) and activated prothrombin complex concentrates (apcc) are used to treat bleeding episodes in the hemophilia patients with inhibitors. aryoseven® is an iranian biogeneric rfviia with homogeneity of efficacy and the nature to novoseven in a comparative trial. the current clinical trial aimed to evaluate the cost...

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

Ardeshiri, Rezvan , Fasih, Belgheis , Habibpanah, Behnaz , Malek, Fatemeh , Managhchi, Mohammad Reza , Salimi, Tahmineh , Tara, Zahra ,

Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the...

2016
Kourosh Goudarzi Pour Fatemeh Malek Peyman Eshghi

We describe a case of a 4-year-old girl with Burkitt's lymphoma, who suffered from a massive gastrointestinal hemorrhage 3 days after chemotherapy. In spite of applying the common practice in correction of coagulopathy, thrombocytopenia persisted and bleeding became life-threatening. In the present case report, we report a successful control of bleeding with a single-dose administration of a bi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید